Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase

Journal of Medicinal Chemistry

Volumn 48, Issue 25, 2005, Pages 8009-8015

  Dayam, Raveendra ^a   Sanchez, Tino ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; ANTIRETROVIRUS AGENT; BETA DIKETO ACID DERIVATIVE; INTEGRASE INHIBITOR; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CATALYSIS; CRYSTALLOGRAPHY; DATA BASE; DRUG DESIGN; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME MECHANISM; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; IC 50; IN VITRO STUDY; MOLECULAR MODEL; PHARMACOPHORE; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

CELL LINE; DATABASES, FACTUAL; DRUG DESIGN; FURANS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HUMANS; HYDROGEN BONDING; KETO ACIDS; MODELS, MOLECULAR; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 29144509688     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050837a     Document Type: Article

References (38)

1. Brown, P. O. Integration. Retroviruses; Cold Spring Harbor Press: Cold Spring Harbor: Woodbury, NY, 1999; pp 161-203.
2. Neamati, N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin. Ther. Pat. 2002, 12, 709-724.
3. Dayam, R.; Neamati, N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr. Pharm. Des. 2003, 9, 1789-1802.
4. Gupta, S. P.; Nagappa, A. N. Design and development of integrase inhibitors as anti-HIV agents. Curr. Med. Chem. 2003, 10, 1779-1794.
5. Pommier, Y.; Johnson, A. A.; Marchand, C. Integrase inhibitors to treat HIV/AIDS. Nat. Rev. Drug Discovery 2005, 4, 236-248.
6. Yoshinaga, T. S.; Fujishita, T.; Fujiwara, T. In Vitro Activity of a New HIV-I Integrase Inhibitor in Clinical Development. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002.
7. Young, S. L-870,810: A Potent Antiviral HIV Integrase Inhibitor with Potential Clinical Utility. Presented at the XIV International AIDS Conference, West Point, PA, 2002.
8. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646-650.
9. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A.; Tussey, L.; Schleif, W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528-532.
10. Milne, G. W.; Nicklaus, M. C.; Wang, S. Pharmacophores in drug design and discovery. SAR QSAR Environ. Res. 1998, 9, 23-38.
11. Fang, X.; Wang, S. A Web-based 3D-database pharmacophore searching tool for drug discovery. J. Chem. Inf. Comput. Sci. 2002, 42, 192-198.
12. Guner, O. F. Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, 2000.
13. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
14. Langer, T.; Krovat, E. M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discovery Dev. 2003, 6, 370-376.
15. Lengauer, T.; Lemmen, C.; Rarey, M.; Zimmermann, M. Novel technologies for virtual screening. Drug Discovery Today 2004, 9, 27-34.
16. Lyne, P. D.; Kenny, P. W.; Cosgrove, D. A.; Deng, C.; Zabludoff, S.; Wendoloski, J. J.; Ashwell, S. Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening. J. Med. Chem. 2004, 47, 1962-1968.
17. Dror, O.; Shulman-Peleg, A.; Nussinov, R.; Wolfson, H. J. Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr. Med. Chem. 2004, 11, 71-90.
18. Patel, Y.; Gillet, V. J.; Bravi, G.; Leach, A. R. A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J. Comput.-Aided Mol. Des. 2002, 16, 653-681.
19. van Drie, J. H. Pharmacophore discovery-lessons learned. Curr. Pharm. Des. 2003, 9, 1649-1664.
20. Nicklaus, M. C.; Neamati, N.; Hong, H.; Mazumder, A.; Sunder, S.; Chen, J.; Milne, G. W.; Pommier, Y. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J. Med. Chem. 1997, 40, 920-929.
21. Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Nicklaus, M. C.; Milne, G. W.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
22. Hong, H.; Neamati, N.; Wang, S.; Nicklaus, M. C.; Mazumder, A.; Zhao, H.; Burke, T. R., Jr.; Pommier, Y.; Milne, G. W. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J. Med. Chem. 1997, 40, 930-936.
23. Hong, H.; Neamati, N.; Winslow, H. E.; Christensen, J. L.; Orr, A.; Pommier, Y.; Milne, G. W. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antiviral Chem. Chemother. 1998, 9, 461-472.
24. Barreca, M. L.; Rao, A.; De Luca, L.; Zappala, M.; Gurnari, C.; Monforte, P.; De Clercq, E.; Van Maele, B.; Debyser, Z.; Witvrouw, M.; Briggs, J. M.; Chimirri, A. Efficient 3D database screening for novel HIV-1IN inhibitors. J. Chem. Inf. Comput. Sci. 2004, 44, 1450-1455.
25. Dayam, R.; Sanchez, T.; Clement, O.; Shoemaker, R.; Sei, S.; Neamati, N. β-Diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J. Med. Chem. 2005, 48, 111-120.
26. Carlson, H. A.; Masukawa, K. M.; Rubins, K.; Bushman, F. D.; Jorgensen, W. L.; Lins, R. D.; Briggs, J. M.; McCammon, J. A. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 2000, 43, 2100-2114.
27. Deng, J.; Lee, K. W.; Sanchez, T.; Cui, M.; Neamati, N.; Briggs, J. M. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J. Med. Chem. 2005, 48, 1496-1505.
28. Billich, A. S-1360 Shionogi-GlaxoSmithKline. Curr. Opin. Invest. Drugs 2003, 4, 206-209.
29. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
30. Nissink, J. W.; Murray, C.; Hartshorn, M.; Verdonk, M. L.; Cole, J. C.; Taylor, R. A new test set for validating predictions of protein-ligand interaction. Proteins 2002, 49, 457-471.
31. Zhao, H.; Neamati, N.; Hong, H.; Mazumder, A.; Wang, S.; Sunder, S.; Milne, G. W.; Pommier, Y.; Burke, T. R., Jr. Coumarin-based inhibitors of HIV integrase. J. Med. Chem. 1997, 40, 242-249.
32. Tarkowski, A.; Gunnarsson, K.; Stalhandske, T. Effects of LS-2616 administration upon the autoimmune disease of (NZB × NZW) F1 hybrid mice. Immunology 1986, 59, 589-594.
33. Bergh, J. C.; Totterman, T. H.; Termander, B. C.; Strandgarden, K. A.; Gunnarsson, P. O.; Nilsson, B. I. The first clinical pilot study of roquinimex (Linomide) in cancer patients with special focus on immunological effects. Cancer Invest. 1997, 15, 204-211.
34. Jean, A. K.; Thomas, T.; David, B.; Paul, H.; Kurt, H.; Beat, W.; Ludvik, L.; Gerard, S.; Kalus, G.; Peter, W. H. Guanidine Derivatives. Compositions and Use; Hoffmann La Roche: Nutley, NJ, 1993.
35. Gelasco, A.; Pecoraro, V. L. [Mn(III)(2-OHsalpn)]2 is an efficient functional-model for the manganese catalases. J. Am. Chem. Soc. 1993, 115, 7928-7929.
36. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043.
37. Long, Y. Q.; Jiang, X. H.; Dayam, R.; Sanchez, T.; Shoemaker, R.; Sei, S.; Neamati, N. Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: Implication for binding to two metal ions on the active site of integrase. J. Med. Chem. 2004, 47, 2561-2573.
38. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.